HCA Healthcare's Sarah Cannon Cancer Institute Implements New Outpatient Model For CAR T-Cell Therapy
Portfolio Pulse from Happy Mohamed
HCA Healthcare's Sarah Cannon Cancer Institute has transitioned over 75% of its CAR T-cell therapy patients to outpatient monitoring, saving 1,200 hospital bed days for the first 100 patients and avoiding hospitalization for 20% of patients. This was achieved through a new integrated management process and technology from Best Buy Health's Current Health platform for at-home monitoring. The initiative, piloted at four sites, aims to improve patient care and meet the demand for cell therapies. HCA plans to expand this model to more sites.
February 22, 2024 | 10:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HCA Healthcare's successful transition of CAR T-cell therapy to outpatient settings could lead to operational efficiencies and enhanced patient care, potentially improving its market position and financial performance.
The successful implementation of an outpatient model for CAR T-cell therapy by HCA Healthcare demonstrates innovation in patient care and operational efficiency. By saving hospital bed days and avoiding hospitalizations, HCA is likely to see reduced costs and improved patient satisfaction, which could positively impact its financial performance and strengthen its market position in the healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90